title: Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells.
authors.affiliation: South Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions, South Carolina College of Pharmacy, University of South Carolina, Columbia.
authors.forename: Charles L
authors.initials: CL
authors.lastname: Bennett
authors.affiliation: Division of Surgery, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston.
authors.forename: Stephen Y
authors.initials: SY
authors.lastname: Lai
authors.affiliation: Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana.
authors.forename: Oliver
authors.initials: O
authors.lastname: Sartor
authors.affiliation: South Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions, South Carolina College of Pharmacy, University of South Carolina, Columbia.
authors.forename: Peter
authors.initials: P
authors.lastname: Georgantopoulos
authors.affiliation: Oncology Analytics Inc, Plantation, Florida.
authors.forename: William J
authors.initials: WJ
authors.lastname: Hrushesky
authors.affiliation: Clinic for Radiation Oncology, Universitätsklinikum, Freiburg, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Henke
authors.affiliation: Department of Medicine, University of Nebraska Medical Center, Omaha.
authors.forename: James O
authors.initials: JO
authors.lastname: Armitage
mesh_terms: D000047:Academies and Institutes; D000740:Anemia / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects; D015153:Blotting, Western / Q000592:standards; D032921:Consensus; D015975:Consensus Development Conferences, NIH as Topic; D004345:Drug Industry; D004921:Erythropoietin / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D006397:Hematinics / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D015588:Observer Variation; D011237:Predictive Value of Tests; D017467:Receptors, Erythropoietin / Q000819:agonists / Q000235:genetics / Q000378:metabolism*; D015203:Reproducibility of Results; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000592:standards; D018570:Risk Assessment; D014481:United States
chemical_list: D000970:Antineoplastic Agents; D006397:Hematinics; D017467:Receptors, Erythropoietin; D004921:Erythropoietin